{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T03:11:30Z","timestamp":1788577890888,"version":"build-2803163510"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T00:00:00Z","timestamp":1647388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T00:00:00Z","timestamp":1647388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100011725","name":"servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Child Psychiatry Hum Dev"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s10578-022-01328-5","type":"journal-article","created":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T04:43:35Z","timestamp":1647405815000},"page":"1360-1372","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["A Phase III Study of Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents Aged Between 7 and 17 Years with Autism Spectrum Disorder (SIGN 1 Trial): Participant Baseline Characteristics"],"prefix":"10.1007","volume":"54","author":[{"given":"Christina","family":"Georgoula","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maite","family":"Ferrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bozena","family":"Pietraszczyk-Kedziora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amaia","family":"Hervas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Marret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiomar","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Rosier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Crutel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Besse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina Albarr\u00e1n","family":"Severo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Ravel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquin","family":"Fuentes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,16]]},"reference":[{"key":"1328_CR1","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders (DSM-5\u00ae) (American Psychiatric Pub)","DOI":"10.1176\/appi.books.9780890425596"},{"key":"1328_CR2","doi-asserted-by":"publisher","first-page":"274","DOI":"10.3390\/brainsci10050274","volume":"10","author":"F Chiarotti","year":"2020","unstructured":"Chiarotti F, Venerosi A (2020) Epidemiology of autism spectrum disorders: a review of worldwide prevalence estimates since 2014. Brain Sci 10:274","journal-title":"Brain Sci"},{"key":"1328_CR3","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1002\/aur.239","volume":"5","author":"M Elsabbagh","year":"2012","unstructured":"Elsabbagh M, Divan G, Koh YJ, Kim YS, Kauchali S, Marc\u00edn C et al (2012) Global prevalence of autism and other pervasive developmental disorders. Autism Res 5:160\u2013179","journal-title":"Autism Res"},{"key":"1328_CR4","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s00787-020-01539-y","volume":"30","author":"J Fuentes","year":"2021","unstructured":"Fuentes J, Basurko A, Isasa I, Galende I, Muguerza MD, Garc\u00eda-Primo P et al (2021) The ASDEU autism prevalence study in northern Spain. Eur Child Adolesc Psychiatry 30:579\u2013589","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"1328_CR5","unstructured":"ASDEU (2021) Autism spectrum disorders in the European Union - prevalence. http:\/\/asdeu.eu\/. Accessed 10 May 2021"},{"key":"1328_CR6","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1017\/S003329171400172X","volume":"45","author":"AJ Baxter","year":"2015","unstructured":"Baxter AJ, Brugha T, Erskine HE, Scheurer RW, Vos T, Scott JG (2015) The epidemiology and global burden of autism spectrum disorders. Psychol Med 45:601","journal-title":"Psychol Med"},{"key":"1328_CR7","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1111\/j.1469-8749.2007.00726.x","volume":"49","author":"G Oliveira","year":"2007","unstructured":"Oliveira G, Ata\u00edde A, Marques C, Miguel TS, Coutinho AM, Mota-Vieira L et al (2007) Epidemiology of autism spectrum disorder in Portugal: prevalence, clinical characterization, and medical conditions. Dev Med Child Neurol 49:726\u2013733","journal-title":"Dev Med Child Neurol"},{"key":"1328_CR8","first-page":"1211","volume":"390","author":"GBD","year":"2016","unstructured":"GBD (2016) Disease and Injury Incidence and Prevalence Collaborators (2017) Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet 390:1211\u20131259","journal-title":"The Lancet"},{"key":"1328_CR9","unstructured":"American Psychiatric Association (2020) Autism often accompanied by other conditions. Available at https:\/\/www.psychiatry.org\/news-room\/apa-blogs\/apa-blog\/2018\/10\/autism-often-accompanied-by-other-conditions. Accessed 10 May 2021"},{"key":"1328_CR10","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.2147\/NDT.S84585","volume":"12","author":"SE Fitzpatrick","year":"2016","unstructured":"Fitzpatrick SE, Srivorakiat L, Wink LK, Pedapati EV, Erickson CA (2016) Aggression in autism spectrum disorder: presentation and treatment options. Neuropsychiatr Dis Treat 12:1525\u20131538","journal-title":"Neuropsychiatr Dis Treat"},{"key":"1328_CR11","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1007\/s10803-015-2402-0","volume":"45","author":"LA Schieve","year":"2015","unstructured":"Schieve LA, Clayton HB, Durkin MS, Wingate MS, Drews-Botsch C (2015) Comparison of perinatal risk factors associated with autism spectrum disorder (ASD), intellectual disability (ID), and co-occurring ASD and ID. J Autism Dev Disord 45:2361\u20132372","journal-title":"J Autism Dev Disord"},{"key":"1328_CR12","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1007\/s10803-015-2486-6","volume":"45","author":"MM van Bakel","year":"2015","unstructured":"van Bakel MM, Delobel-Ayoub M, Cans C, Assouline B, Jouk PS, Raynaud JP et al (2015) Low but increasing prevalence of autism spectrum disorders in a French area from register-based data. J Autism Dev Disord 45:3255\u20133261","journal-title":"J Autism Dev Disord"},{"key":"1328_CR13","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1177\/1362361318791279","volume":"23","author":"E Rydzewska","year":"2019","unstructured":"Rydzewska E, Hughes-McCormack LA, Gillberg C, Henderson A, MacIntyre C, Rintoul J et al (2019) Prevalence of sensory impairments, physical and intellectual disabilities, and mental health in children and young people with self\/proxy-reported autism: observational study of a whole country population. Autism 23:1201\u20131209","journal-title":"Autism"},{"key":"1328_CR14","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3389\/fpsyt.2019.00107","volume":"10","author":"F Muratori","year":"2019","unstructured":"Muratori F, Turi M, Prosperi M, Narzisi A, Valeri G, Guerrera S et al (2019) Parental perspectives on psychiatric comorbidity in preschoolers with autism spectrum disorders receiving publicly funded mental health services. Front Psychiatry 10:107","journal-title":"Front Psychiatry"},{"key":"1328_CR15","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1080\/08039488.2018.1444087","volume":"72","author":"BH Hansen","year":"2018","unstructured":"Hansen BH, Oerbeck B, Skirbekk B, Petrovski B, Kristensen H (2018) Neurodevelopmental disorders: prevalence and comorbidity in children referred to mental health services. Nord J Psychiatry 72:285\u2013291","journal-title":"Nord J Psychiatry"},{"key":"1328_CR16","doi-asserted-by":"publisher","first-page":"e0207286","DOI":"10.1371\/journal.pone.0207286","volume":"13","author":"B Rosello","year":"2018","unstructured":"Rosello B, Berenguer C, Baixauli I, Colomer C, Miranda A (2018) ADHD symptoms and learning behaviors in children with ASD without intellectual disability. A mediation analysis of executive functions. PLoS ONE 13:e0207286","journal-title":"PLoS ONE"},{"key":"1328_CR17","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/aur.1361","volume":"7","author":"MJ Hollocks","year":"2014","unstructured":"Hollocks MJ, Jones CR, Pickles A, Baird G, Happ\u00e9 F, Charman T et al (2014) The association between social cognition and executive functioning and symptoms of anxiety and depression in adolescents with autism spectrum disorders. Autism Res 7:216\u2013228","journal-title":"Autism Res"},{"key":"1328_CR18","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.dld.2015.11.026","volume":"48","author":"F Fulceri","year":"2016","unstructured":"Fulceri F, Morelli M, Santocchi E, Cena H, Del Bianco T, Narzisi A et al (2016) Gastrointestinal symptoms and behavioral problems in preschoolers with autism spectrum disorder. Dig Liver Dis 48:248\u2013254","journal-title":"Dig Liver Dis"},{"key":"1328_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5607\/en.2016.25.1.1","volume":"25","author":"HR Park","year":"2016","unstructured":"Park HR, Lee JM, Moon HE, Lee DS, Kim B-N, Kim J et al (2016) A short review on the current understanding of autism spectrum disorders. Exp Neurobiol 25:1\u201313","journal-title":"Exp Neurobiol"},{"key":"1328_CR20","doi-asserted-by":"crossref","unstructured":"Fuentes J, Herv\u00e1s A, Howlin P (2020) ESCAP practice guidance for autism: a summary of evidence-based recommendations for diagnosis and treatment. Eur Child Adolesc Psychiatry: ePub ahead of print","DOI":"10.1007\/s00787-020-01587-4"},{"key":"1328_CR21","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1080\/09540261.2018.1432574","volume":"30","author":"RJ Landa","year":"2018","unstructured":"Landa RJ (2018) Efficacy of early interventions for infants and young children with, and at risk for, autism spectrum disorders. Int Rev Psychiatry 30:25\u201339","journal-title":"Int Rev Psychiatry"},{"key":"1328_CR22","first-page":"e3901","volume":"11","author":"S Medavarapu","year":"2019","unstructured":"Medavarapu S, Marella LL, Sangem A, Kairam R (2019) Where is the evidence? A narrative literature review of the treatment modalities for autism spectrum disorders. Cureus 11:e3901","journal-title":"Cureus"},{"key":"1328_CR23","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1097\/YCO.0000000000000043","volume":"27","author":"BJ Tonge","year":"2014","unstructured":"Tonge BJ, Bull K, Brereton A, Wilson R (2014) A review of evidence-based early intervention for behavioural problems in children with autism spectrum disorder: the core components of effective programs, child-focused interventions and comprehensive treatment models. Curr Opin Pychiatry 27:158\u2013165","journal-title":"Curr Opin Pychiatry"},{"key":"1328_CR24","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1007\/s10803-019-03949-7","volume":"50","author":"C Perihan","year":"2020","unstructured":"Perihan C, Burke M, Bowman-Perrott L, Bicer A, Gallup J, Thompson J et al (2020) Effects of cognitive behavioral therapy for reducing anxiety in children with high functioning ASD: a systematic review and meta-analysis. J Autism Dev Disord 50:1958\u20131972","journal-title":"J Autism Dev Disord"},{"key":"1328_CR25","doi-asserted-by":"publisher","first-page":"S124","DOI":"10.1542\/peds.2015-2851K","volume":"137","author":"LK Fung","year":"2016","unstructured":"Fung LK, Mahajan R, Nozzolillo A, Bernal P, Krasner A, Jo B et al (2016) Pharmacologic treatment of severe irritability and problem behaviors in autism: a systematic review and meta-analysis. Pediatrics 137:S124\u2013S135","journal-title":"Pediatrics"},{"key":"1328_CR26","unstructured":"EMA (2017) Haldol summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/referral\/haldol-article-30-referral-annex-iii_en.pdf. Accessed 10 May 2021"},{"key":"1328_CR27","unstructured":"EMA (2018) Slenyto summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/slenyto-epar-product-information_en.pdf. Accessed 10 May 2021"},{"key":"1328_CR28","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3389\/fped.2014.00070","volume":"2","author":"G Cellot","year":"2014","unstructured":"Cellot G, Cherubini E (2014) GABAergic signaling as therapeutic target for autism spectrum disorders. Front Pediatr 2:70","journal-title":"Front Pediatr"},{"key":"1328_CR29","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/16697","volume":"397","author":"C Rivera","year":"1999","unstructured":"Rivera C, Voipio J, Payne JA, Ruusuvuori E, Lahtinen H, Lamsa K et al (1999) The K+\/Cl- co-transporter KCC2 renders GABA hyperpolarizing during neuronal maturation. Nature 397:251\u2013255","journal-title":"Nature"},{"key":"1328_CR30","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/nrn920","volume":"3","author":"Y Ben-Ari","year":"2002","unstructured":"Ben-Ari Y (2002) Excitatory actions of gaba during development: the nature of the nurture. Nat Rev Neurosci 3:728\u2013739","journal-title":"Nat Rev Neurosci"},{"key":"1328_CR31","unstructured":"FDA (2009) BUMEX bumetanide tablets packaging label. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/018225s024lbl.pdf. Accessed 10 May 2021"},{"key":"1328_CR32","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/nm1301","volume":"11","author":"VI Dzhala","year":"2005","unstructured":"Dzhala VI, Talos DM, Sdrulla DA, Brumback AC, Mathews GC, Benke TA et al (2005) NKCC1 transporter facilitates seizures in the developing brain. Nat Med 11:1205\u20131213","journal-title":"Nat Med"},{"key":"1328_CR33","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1152\/physrev.00017.2006","volume":"87","author":"Y Ben-Ari","year":"2007","unstructured":"Ben-Ari Y, Gaiarsa JL, Tyzio R, Khazipov R (2007) GABA: a pioneer transmitter that excites immature neurons and generates primitive oscillations. Physiol Rev 87:1215\u20131284","journal-title":"Physiol Rev"},{"key":"1328_CR34","doi-asserted-by":"publisher","first-page":"e202","DOI":"10.1038\/tp.2012.124","volume":"2","author":"\u00c9 Lemonnier","year":"2012","unstructured":"Lemonnier \u00c9, Degrez C, Phelep M, Tyzio R, Josse F, Grandgeorge M et al (2012) A randomised controlled trial of bumetanide in the treatment of autism in children. Transl Psychiatry 2:e202\u2013e202","journal-title":"Transl Psychiatry"},{"key":"1328_CR35","doi-asserted-by":"publisher","first-page":"e1056","DOI":"10.1038\/tp.2017.10","volume":"7","author":"E Lemonnier","year":"2017","unstructured":"Lemonnier E, Villeneuve N, Sonie S, Serret S, Rosier A, Roue M et al (2017) Effects of bumetanide on neurobehavioral function in children and adolescents with autism spectrum disorders. Transl Psychiatry 7:e1056\u2013e1056","journal-title":"Transl Psychiatry"},{"key":"1328_CR36","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1007\/s10803-020-04709-8","volume":"51","author":"V Crutel","year":"2021","unstructured":"Crutel V, Lambert E, Penelaud P-F, Severo CA, Fuentes J, Rosier A et al (2021) Bumetanide oral liquid formulation for the treatment of children and adolescents with autism spectrum disorder: design of two Phase III studies (SIGN trials). J Autism Dev Disord 51:2959\u20132972","journal-title":"J Autism Dev Disord"},{"key":"1328_CR37","unstructured":"Lord C, Rutter M, DiLavore P, Risi S, Gotham K, Bishop S (2012) Autism Diagnostic Observation Schedule\u2013Second Edition (ADOS-2) Western Psychological Corporation (Los Angeles, CA, USA)"},{"key":"1328_CR38","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/BF02172145","volume":"24","author":"C Lord","year":"1994","unstructured":"Lord C, Rutter M, Le Couteur A (1994) Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord 24:659\u2013685","journal-title":"J Autism Dev Disord"},{"key":"1328_CR39","doi-asserted-by":"crossref","unstructured":"Guy W (1976) ECDEU assessment manual for psychopharmacology (US Department of Health, Education, and Welfare, Public Health Service)","DOI":"10.1037\/e591322011-001"},{"key":"1328_CR40","unstructured":"Schopler E, Reichler RJ, Renner BR (2010) The childhood autism rating scale (CARS) (WPS, Los Angeles, CA)"},{"key":"1328_CR41","unstructured":"Constantino JN, Gruber CP (2012) Social responsiveness scale: SRS-2 (WPS, Torrance, CA)"},{"key":"1328_CR42","first-page":"28","volume":"4","author":"J Busner","year":"2007","unstructured":"Busner J, Targum SD (2007) The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry 4:28\u201337","journal-title":"Psychiatry"},{"key":"1328_CR43","unstructured":"European Medicines Agency (2017). Guideline on the clinical development of medicinal products for the treatment of Autism spectrum disorder (ASD). https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-development-medicinal-products-treatment-autism-spectrum-disorder-asd_en.pdf. Accessed 19 Nov 2021"},{"key":"1328_CR44","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/00005650-199902000-00003","volume":"37","author":"JW Varni","year":"1999","unstructured":"Varni JW, Seid M, Rode C (1999) PedsQL: measurement model for the pediatric quality of life inventory. Med Care 37:126\u2013139","journal-title":"Med Care"},{"key":"1328_CR45","unstructured":"WHO (1996) World Health Organization - WHOQOL-BREF: introduction, administration, scoring, and generic version of the assessement. Field trial version: December 1996. https:\/\/www.who.int\/mental_health\/media\/en\/76.pdf. Accessed 10 May 2021"},{"key":"1328_CR46","unstructured":"SAS (2008) SAS Institute. SAS PC software, version 9.2 of the SAS system for Windows. Cary, NC: SAS Institute; 2008"},{"key":"1328_CR47","unstructured":"WHO (2007) World Health Organization - growth reference data for 5\u201319 year olds. https:\/\/www.who.int\/growthref. Accessed 10 May 2021"},{"key":"1328_CR48","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/0269881117741766","volume":"32","author":"OD Howes","year":"2018","unstructured":"Howes OD, Rogdaki M, Findon JL, Wichers RH, Charman T, King BH et al (2018) Autism spectrum disorder: consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology. J Psychopharmacol 32:3\u201329","journal-title":"J Psychopharmacol"},{"key":"1328_CR49","unstructured":"NICE (2014) National Institute for Health and Care Excellence - antipsychotic medication. https:\/\/www.nice.org.uk\/guidance\/cg178\/ifp\/chapter\/Antipsychotic-medication. Accessed 10 May 2021"},{"key":"1328_CR50","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1111\/j.1651-2227.2010.01933.x","volume":"99","author":"E Lemonnier","year":"2010","unstructured":"Lemonnier E, Ben-Ari Y (2010) The diuretic bumetanide decreases autistic behaviour in five infants treated during 3 months with no side effects. Acta Paediatr 99:1885\u20131888","journal-title":"Acta Paediatr"},{"key":"1328_CR51","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1007\/s00213-013-3140-7","volume":"231","author":"ML Murray","year":"2014","unstructured":"Murray ML, Hsia Y, Glaser K, Simonoff E, Murphy DG, Asherson PJ et al (2014) Pharmacological treatments prescribed to people with autism spectrum disorder (ASD) in primary health care. Psychopharmacology 231:1011\u20131021","journal-title":"Psychopharmacology"},{"key":"1328_CR52","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1177\/1362361316673977","volume":"22","author":"CJ Bachmann","year":"2018","unstructured":"Bachmann CJ, Gerste B, Hoffmann F (2018) Diagnoses of autism spectrum disorders in Germany: time trends in administrative prevalence and diagnostic stability. Autism 22:283\u2013290","journal-title":"Autism"},{"key":"1328_CR53","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s10803-019-04328-y","volume":"50","author":"M Delobel-Ayoub","year":"2020","unstructured":"Delobel-Ayoub M, Saemundsen E, Gissler M, Ego A, Moilanen I, Ebeling H et al (2020) Prevalence of autism spectrum disorder in 7-9-year-old children in Denmark, Finland, France and Iceland: a population-based registries approach within the ASDEU project. J Autism Dev Disord 50:949\u2013959","journal-title":"J Autism Dev Disord"},{"key":"1328_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.ss6706a1","volume":"67","author":"J Baio","year":"2018","unstructured":"Baio J, Wiggins L, Christensen DL, Maenner MJ, Daniels J, Warren Z et al (2018) Prevalence of autism spectrum disorder among children aged 8 years - Autism and Developmental Disabilities Monitoring Network, 11 sites, United States, 2014. MMWR Surveill Summ 67:1\u201323","journal-title":"MMWR Surveill Summ"},{"key":"1328_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/DBP.0000000000000117","volume":"36","author":"J Bickel","year":"2015","unstructured":"Bickel J, Bridgemohan C, Sideridis G, Huntington N (2015) Child and family characteristics associated with age of diagnosis of an autism spectrum disorder in a tertiary care setting. J Dev Behav Pediatr 36:1\u20137","journal-title":"J Dev Behav Pediatr"},{"key":"1328_CR56","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1007\/s10803-016-2716-6","volume":"46","author":"D Brett","year":"2016","unstructured":"Brett D, Warnell F, McConachie H, Parr JR (2016) Factors affecting age at ASD diagnosis in UK: no evidence that diagnosis age has decreased between 2004 and 2014. J Autism Dev Disord 46:1974\u20131984","journal-title":"J Autism Dev Disord"},{"key":"1328_CR57","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/cch.12261","volume":"42","author":"E Salomone","year":"2016","unstructured":"Salomone E, Charman T, McConachie H, Warreyn P (2016) Child\u2019s verbal ability and gender are associated with age at diagnosis in a sample of young children with ASD in Europe. Child Care Health Dev 42:141\u2013145","journal-title":"Child Care Health Dev"},{"key":"1328_CR58","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.1097\/00004703-200604002-00005","volume":"27","author":"LD Wiggins","year":"2006","unstructured":"Wiggins LD, Baio J, Rice C (2006) Examination of the time between first evaluation and first autism spectrum diagnosis in a population-based sample. J Dev Behav Pediatr 27:S79-87","journal-title":"J Dev Behav Pediatr"},{"key":"1328_CR59","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1176\/ps.2010.61.8.822","volume":"61","author":"DS Mandell","year":"2010","unstructured":"Mandell DS, Morales KH, Xie M, Lawer LJ, Stahmer AC, Marcus SC (2010) Age of diagnosis among Medicaid-enrolled children with autism, 2001\u20132004. Psychiatr Serv 61:822\u2013829","journal-title":"Psychiatr Serv"},{"key":"1328_CR60","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/DBP.0000000000000097","volume":"35","author":"MO Mazurek","year":"2014","unstructured":"Mazurek MO, Handen BL, Wodka EL, Nowinski L, Butter E, Engelhardt CR (2014) Age at first autism spectrum disorder diagnosis: the role of birth cohort, demographic factors, and clinical features. J Dev Behav Pediatr 35:561\u2013569","journal-title":"J Dev Behav Pediatr"},{"key":"1328_CR61","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s00787-017-1020-0","volume":"26","author":"JB Muskens","year":"2017","unstructured":"Muskens JB, Velders FP, Staal WG (2017) Medical comorbidities in children and adolescents with autism spectrum disorders and attention deficit hyperactivity disorders: a systematic review. Eur Child Adolesc Psychiatr 26:1093\u20131103","journal-title":"Eur Child Adolesc Psychiatr"},{"key":"1328_CR62","doi-asserted-by":"publisher","first-page":"112922","DOI":"10.1016\/j.psychres.2020.112922","volume":"287","author":"MM Hossain","year":"2020","unstructured":"Hossain MM, Khan N, Sultana A, Ma P, McKyer ELJ, Ahmed HU et al (2020) Prevalence of comorbid psychiatric disorders among people with autism spectrum disorder: an umbrella review of systematic reviews and meta-analyses. Psychiatry Res 287:112922","journal-title":"Psychiatry Res"},{"key":"1328_CR63","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/s10803-016-2946-7","volume":"47","author":"JM Madden","year":"2017","unstructured":"Madden JM, Lakoma MD, Lynch FL, Rusinak D, Owen-Smith AA, Coleman KJ et al (2017) Psychotropic medication use among insured children with autism spectrum disorder. J Autism Dev Disord 47:144\u2013154","journal-title":"J Autism Dev Disord"},{"key":"1328_CR64","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.jaac.2020.07.888","volume":"60","author":"JJ Sprengers","year":"2021","unstructured":"Sprengers JJ, Van Andel DM, Zuithoff NP, Keijzer-Veen MG, Schulp AJ, Scheepers FE et al (2021) Bumetanide for core symptoms of autism spectrum disorder (BAMBI): a single center, double-blinded, participant-randomized, placebo-controlled, Phase-2 superiority trial. J Am Acad Child Adolesc Psychiatry 60:865\u2013876","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"1328_CR65","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41398-020-0692-2","volume":"10","author":"L Zhang","year":"2020","unstructured":"Zhang L, Huang CC, Dai Y, Luo Q, Ji Y, Wang K et al (2020) Symptom improvement in children with autism spectrum disorder following bumetanide administration is associated with decreased GABA\/glutamate ratios. Transl Psychiatry 10:9","journal-title":"Transl Psychiatry"},{"key":"1328_CR66","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.conctc.2017.11.005","volume":"9","author":"RG Greenberg","year":"2018","unstructured":"Greenberg RG, Gamel B, Bloom D, BradleyJ JHS, Hinton D et al (2018) Parents\u2019 perceived obstacles to pediatric clinical trial participation: findings from the clinical trials transformation initiative. Contemp Clin Trials Commun 9:33\u201339","journal-title":"Contemp Clin Trials Commun"},{"key":"1328_CR67","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S0140-6736(04)16942-0","volume":"364","author":"PH Caldwell","year":"2004","unstructured":"Caldwell PH, Murphy SB, Butow PN, Craig JC (2004) Clinical trials in children. Lancet 364:803\u2013811","journal-title":"Lancet"},{"key":"1328_CR68","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1016\/S0140-6736(09)61803-1","volume":"374","author":"TP Klassen","year":"2009","unstructured":"Klassen TP, Hartling L, Hamm M, van der Leer JH, Offringa M (2009) StaR Child Health: an initiative for RCTs in children. Lancet 374:1310\u20131312","journal-title":"Lancet"}],"container-title":["Child Psychiatry & Human Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10578-022-01328-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10578-022-01328-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10578-022-01328-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T10:13:38Z","timestamp":1726827218000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10578-022-01328-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,16]]},"references-count":68,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["1328"],"URL":"https:\/\/doi.org\/10.1007\/s10578-022-01328-5","relation":{},"ISSN":["0009-398X","1573-3327"],"issn-type":[{"value":"0009-398X","type":"print"},{"value":"1573-3327","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,16]]},"assertion":[{"value":"21 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Maite Ferrin\u2014research support from Servier; advisory board participation for Novartis. Christina Georgoula, Bozena Pietraszczyk-Kedziora, Amaia Hervas, St\u00e9phane Marret, Guiomar Oliveira, Antoine Rosier\u2014research support from Servier. V\u00e9ronique Crutel, Emmanuelle Besse, Cristina Albarr\u00e1n Severo\u2014employee of Servier. Denis Ravel\u2014employee of Neurochlore. Joaquin Fuentes\u2014research support from Policl\u00ednica Gipuzkoa Foundation, Servier and AIMS-2-Trials project ID 777394. Partial support for attending professional meetings from Policl\u00ednica Gipuzkoa Foundation, ESCAP and AACAP.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants are in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research Involving Human Participants"}}]}}